Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 9;12(4):231–237. doi: 10.14740/cr1282

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2021, Katsuragi et al.

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Mechanical properties of pulmonary arterial smooth muscle cells (PASCMCs) derived from a patient with idiopathic pulmonary arterial hypertension (PAH-PASMCs) in response to macitentan and riociguat treatment. (a) The apparent Young’s modulus normalized with that of untreated cells, logE₀/logE_c of PAH-PASMCs in response to macitentan treatment. (b) α of macitentan-treated PAH-PASMCs. (c) The log E₁ of macitentan-treated PAH-PASMCs. (d) The logE₀/logE_c of riociguat-treated PAH-PASMCs. (e) α of riociguat-treated PAH-PASMCs. (f) The logE₁ of riociguat-treated PAH-PASMCs. (g) The logE₀/log E_c of PAH-PASMCs with combination treatment. (h) α of PAH-PASMCs with combination treatment. (i) The logE₁ of PAH-PASMCs with combination treatment. *P < 0.05 vs. DMSO-treated PASMCs by ANOVA. **P < 0.05 by Student’s t-test. DMSO: dimethylsulfoxide; ANOVA: analysis of variance.